APA

Ichikawa T., Kurozumi K., Michiue H., Ishida J., Maeda Y., Kondo E., Kawasaki A. & Date I. (20150803). Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. : Clinical neurology and neurosurgery.

Chicago

Ichikawa Tomotsugu, Kurozumi Kazuhiko, Michiue Hiroyuki, Ishida Joji, Maeda Yoshinobu, Kondo Eisei, Kawasaki Akihiro and Date Isao. 20150803. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. : Clinical neurology and neurosurgery.

Harvard

Ichikawa T., Kurozumi K., Michiue H., Ishida J., Maeda Y., Kondo E., Kawasaki A. and Date I. (20150803). Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. : Clinical neurology and neurosurgery.

MLA

Ichikawa Tomotsugu, Kurozumi Kazuhiko, Michiue Hiroyuki, Ishida Joji, Maeda Yoshinobu, Kondo Eisei, Kawasaki Akihiro and Date Isao. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. : Clinical neurology and neurosurgery. 20150803.